U.S. court rejects Teva's patent-infringement claims on Copaxone

(Reuters) - Teva Pharmaceutical Industries Ltd said on Monday a U.S. court rejected four of the Israel-based drugmaker's claims of patent infringement on its top-selling multiple sclerosis treatment.